โ† All deals

INSMED INC

Public Equity (NASDAQ)BiotechnologyPublic CompanyRare Diseases
๐Ÿ“ Bridgewater Township, New Jersey, United States
StreetZero Signal 68
Be the first to signal interest

About INSMED INC

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is a first-in-disease treatment, with additional pipeline focus including ARIKAYCE for nontuberculous mycobacteria lung disease. The company is publicly traded on NASDAQ under ticker INSM and maintains headquarters in Bridgewater Township, New Jersey.

LATEST FUNDINGRule 144
$14.7M
Announced 2026-11-19
TOTAL RAISED$4.57B
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for INSMED INC.

Free plan includes 3 full deal profiles every month.

EMPLOYEESโ€”
FOUNDEDโ€”
HQBridgewater Township, New Jersey, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyPublic CompanyRare DiseasesBiopharmaceutical

Key highlights

  • Publicly traded on NASDAQ: INSM with focus on serious and rare diseases.
  • Completed $14.7M Rule 144 placement with undisclosed investors.
  • Total funding of $4.57B across 17 rounds including multiple post-IPO equity raises.
  • First commercial product targets unmet needs in nontuberculous mycobacteria lung disease.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account